London, UK – Cancer is a deadly disease that takes the lives of millions of people each year. While there are many different types of cancer, they all have one thing in common: they are caused by the abnormal growth of cells in the body. Cancer can develop in almost any type of cell in the body and can spread from its original site to other parts of the body. This process is called metastasis. Cancer that has spread from its original site to other parts of the body is called metastatic cancer.
Many people with cancer will have only one type of cancer. However, some people may develop more than one type of cancer. This is called multicentric cancer. Grand Pacific Trade Broker Mark Hoffmann pointed out that today, cancer is the leading cause of death in developed countries and the second leading cause of death in developing countries, which means more needs to be invested n its treatment. It is expected that by 2030, cancer will become the leading cause of death worldwide.
There are many different types of cancer, but the four most common are lung cancer, breast cancer, colorectal cancer, and prostate cancer. These four types of cancer account for more than half of all cancer deaths each year. Very unfortunately, lung cancer is the leading cause of cancer death in men and women. Breast cancer is the second leading cause of cancer death in women. Colorectal cancer is the third leading cause of cancer death in both men and women. Prostate cancer is the fourth leading cause of cancer death in men.
Today, cancer can be treated with surgery, radiation therapy, chemotherapy, or a combination of these treatments. Surgery is the most common type of treatment for cancer. It is often used to remove the tumor and any nearby lymph nodes that contain cancer cells. Radiation therapy uses high-energy beams to kill cancer cells. Chemotherapy uses drugs to kill cancer cells.
It is a highly complex disease, and there is still much that is not known about it. However, there are many ways that you can reduce your risk of developing cancer.
There are many startups (some are now full-fledged companies) that are working on cancer. Hoffmann shared that some of these startups are working on new ways to treat cancer, while others are working on early detection methods or new ways to prevent cancer.
Some of the most promising cancer startups include:
- GRAIL is a startup that is developing a blood test that can detect multiple types of cancer at early stages.
- Guardant Health is a startup that is developing a blood test that can detect multiple types of cancer at early stages.
- Freenome is a startup that is developing a blood test that can detect multiple types of cancer at early stages.
- CancerIQ is a startup that is developing a tool to help people understand their risk of developing cancer and take steps to reduce that risk.
- Prevencio is a startup that is developing a blood test that can detect multiple types of cancer at early stages.
These are just a few out of many promising startups working on cancer. With so much promising work being done, there is hope that cancer will one day be a thing of the past.
The major hurdle in the development of effective immunotherapies for cancer has been the lack of funds. They are very expensive to develop and, most of the time, fail in clinical trials. However, there are a few companies that are working on this front and have made significant progress.
Epitopea, a medical technology company based in Cambridge, has secured £10.3 million in a seed funding round. The Medtech startup is developing off-the-shelf cancer immunotherapies that are intended to treat a wide range of patients. The influx of cash will be spent on further developing the company’s research and development efforts, as well as increasing the executive team.
Eptiopea is focused on tumor-specific antigens (TSAs), molecules found in many types of cancer, and using them to develop tumor-specific targets for immunotherapy treatment, building upon work done exclusively at the Université de Montréal. This way, the developed cancer treatments will be able to specifically target and kill only the malignant cells, while the non-cancerous or healthy cells will be left unharmed.
“The excellent work of Epitopea’s co-founders, Université de Montréal scientists Drs. Claude Perreault and Pierre Thibault have created a tremendous and potentially revolutionary opportunity for future cancer patients,” said the Epitopea CEO, Dr. Jon Moore.
The £10.3 million funding round for Epitopea was led by a transatlantic syndicate that included Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital (CIC), and the Fonds de solidarité FTQ. Novateur Ventures and the Harrington Discovery Institute/University Health Holdings also took part. Dr. Laurence Rulleau of CTI Life Sciences said, “we are confident that Epitopea will revolutionize the way cancer patients are treated with therapeutics vaccines and other immunotherapies, allowing them to enjoy a better quality of life.”
Disclaimer: Our content is intended to be used for informational purposes only. It is very important to do your own research before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, or independently research and verify, any information that you find on this article and wish to rely upon, whether for the purpose of making an investment decision or otherwise.